Which patients should receive Synagis?
In general, Synagis is recommended for the following infants: Infants younger than 24 months years of age with chronic lung disease (CLD) who have required medical therapy (supplemental oxygen, bronchodilator, diuretic or corticosteroid therapy) for CLD within six months before the start of RSV season. Infants who are 12 months of age or younger with hemodynamically significant cyanotic and acyanotic congenital heart disease. Hemodynamically significant is defined as infants receiving medication to control congestive heart failure or infants with moderate to severe pulmonary hypertension. Infants born at 28 weeks of gestation or earlier who are less than 12 months of age at the start of RSV season. Infants born between 29 to 32 weeks gestation who are 6 months of age or less at the start of RSV season. Infants born between 32 to 35 weeks gestation (between 32 weeks, 1 day and 35 weeks, 0 days) who are 6 months of age or less at the start of RSV season with two or more additional risk f
